On October 31, Profectus BioSciences, Inc. announced it has received millions of dollars to develop an Ebola vaccine.
The Pentagon awarded the contract through its Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a program that develops and stockpiles vaccines to be used on soldiers.
“The $9.5 million award has been made with Battelle Memorial Institute through the Chemical, Biological, Radiological, & Nuclear Defense Information Analysis Center,” a PRNewswire released on Friday states.
CBRNIAC is part of the Pentagon’s Defense Technical Information Center. DTIC provides a “suite of services” to defense contractors and academic institutions. It also provides services of the Homeland Security “community.”
“We are continuing to develop a trivalent vaccine that will protect our service members and DoD civilians against the major filovirus threats: Ebola Zaire, Ebola Sudan, and Marburg viruses,” said the manager of the Pentagon’s Medical Countermeasure Systems-Joint Vaccine Acquisition Program. “The DoD is optimistic that its long-term commitment to identifying and supporting safe and effective trivalent filovirus vaccines is coming to fruition and remains supportive to advancing the Profectus BioSciences trivalent Ebola/Marburg vaccine into human clinical trials as rapidly as possible.”
Earlier in the week, the Medical Countermeasure Systems-Joint Vaccine Acquisition Program awarded Colorado State University’s Biopharmaceutical Manufacturing and Academic Resource Center $2 million to work on an Ebola and Marburg vaccine. “Among MCS-JVAP’s requirements is to develop a vaccine to protect soldiers from exposure to filoviruses, which cause several types of hemorrhagic fever,” Global Biodefense reports.
From Military Guinea Pigs to Civilians
The move by the Pentagon represents the militarization of Ebola vaccine effort. “While the primary purpose of the Ebola vaccine would be to protect U.S. soldiers, it is possible that such a vaccine could be used for endemic outbreaks of filovirus infection,” the website notes.
Soldiers will become guinea pigs for a vaccine destined for public application. On October 27, USA Today reported the center at CSU “develops and stockpiles vaccines and countermeasures that can be used to protect soldiers, but the research ultimately will benefit civilians.”
Written by KURT NIMMO
Read more at Infowars